News | June 07, 2021
Bayer acquires Noria and PSMA Therapeutics
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)